Publications by authors named "Hideki Suganami"

Are you Hideki Suganami?   Register this Author

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Expert Opin Pharmacother 2014 Apr 11;15(6):749-66. Epub 2014 Feb 11.
Yamaguchi University Graduate School of Medicine, Division of Endocrinology, Metabolism, Hematological Science and Therapeutics , 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505 , Japan +81 836 22 2250 (office) ; +81 836 22 2256 ;

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Atherosclerosis 2016 06 26;249:36-43. Epub 2016 Feb 26.
Laboratory for Systems Biology and Medicine (LSBM), Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan. Electronic address:

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
J Clin Lipidol 2018 Jan - Feb;12(1):173-184. Epub 2017 Oct 28.
Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan; Department of Cardiovascular Medicine, Rinku General Medical Center, Izumisano, Japan.